InvestorsHub Logo
Followers 6
Posts 4111
Boards Moderated 0
Alias Born 12/14/2009

Re: blueyedcatch post# 93188

Wednesday, 02/20/2019 9:21:12 PM

Wednesday, February 20, 2019 9:21:12 PM

Post# of 108192
Because the efficacy hasn't been strong enough relative to other therapies and combo regimens in development. If the trial data had been stronger, ADXS would have a partner for AXAL and PSA and Amgen would not have decided it was better to loose 65m than put a another dime in NEO because the probability for commercial success is low.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ADXS News